Methods for making compound particles

Patent metadata

Field	Value
Publication number	US-9918957-B2
Application number	US-201715499397-A
Country	US
Kind code	B2
Filing date	Apr 27, 2017
Priority date	Jun 4, 2015
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm 3 and about 0.15 g/cm 3 , and/or a specific surface area (SSA) of at least 18 m 2 /g, 20 m 2 /g, 25 m 2 /g, 30 m 2 /g, 32 m 2 /g, 34 m 2 /g, or 35 m 2 /g. Methods for making and using such compositions are also provided.

First claim

We claim:

1. A method for making paclitaxel or docetaxel particles, comprising:
(a) introducing (i) a solution comprising at least one solvent and at least one solute comprising paclitaxel or docetaxel into a nozzle inlet, and (ii) a compressed fluid into an inlet of a vessel defining a pressurizable chamber;
(b) passing the solution out of a nozzle orifice and into the pressurizable chamber to produce an output stream of atomized droplets, wherein the nozzle orifice is located between 4 mm and 20 mm from a sonic energy source located within the output stream, wherein the sonic energy source produces sonic energy with an amplitude between 10% and 60% during the passing, and wherein the nozzle orifice has a diameter of between 20 μm and 125 μm; and
(c) contacting the atomized droplets with the compressed fluid, to cause depletion of the solvent from the atomized droplets, to produce paclitaxel or docetaxel particles,
wherein steps (a), (b), and (c) are carried out under supercritical temperature and pressure for the compressed fluid.

2. The method of claim 1 , further comprising:
(d) contacting the paclitaxel or docetaxel particles produced in step (c) with an anti-solvent to cause further depletion of the solvent from the paclitaxel or docetaxel particles, wherein step (d) is carried out under supercritical temperature and pressure for the anti-solvent.

3. The method of claim 1 , wherein a flow rate of the solution through the nozzle has a range from about 0.5 mL/min to about 30 mL/min.

4. The method of claim 1 , wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.

5. The method of claim 1 , wherein the sonic energy source has a frequency of between about 18 kHz and about 22 kHz.

6. The method of claim 2 , further comprising:
(e) receiving the plurality of paclitaxel or docetaxel particles through the outlet of the pressurizable chamber; and
(f) collecting the plurality of particles in a collection device.

7. The method of claim 1 , wherein the compressed fluid is super critical carbon dioxide.

8. The method of claim 2 , wherein the anti-solvent is super critical carbon dioxide.

9. The method of claim 1 , wherein the paclitaxel or docetaxel particles are paclitaxel particles and the solvent comprises acetone.

10. The method of claim 1 , wherein the paclitaxel or docetaxel particles are docetaxel particles and the solvent comprises ethanol.

11. The method of claim 2 , wherein the paclitaxel or docetaxel particles are paclitaxel particles and the solvent comprises acetone.

12. The method of claim 2 , wherein the paclitaxel or docetaxel particles are docetaxel particles and the solvent comprises ethanol.

13. The method of claim 11 , wherein the compressed fluid and the anti-solvent are super critical carbon dioxide.

14. The method of claim 12 , wherein the compressed fluid and the anti-solvent are super critical carbon dioxide.

15. The method of claim 13 , wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.

16. The method of claim 15 , wherein the sonic energy source has a frequency of between about 18 kHz and about 22 kHz.

17. The method of claim 14 , wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.

18. The method of claim 17 , wherein the sonic energy source has a frequency of between about 18 kHz and about 22 kHz.

Assignees

• Crititech Inc

Inventors

• Baltezor Michael
• Farthing Joseph
• Sittenauer Jake
• Espinosa Jahna
• Campbell Samuel
• Mcclorey Matthew
• Fischer Julia K
• Williams Mark D

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• B01J19/10

  employing sonic or ultrasonic vibrations · CPC title

• A61K9/10 Primary

  Dispersions; Emulsions · CPC title

• B01J2/04

  in a gaseous medium {(if combined with suspending the material in a gas, e.g. fluidised beds B01J2/16)} · CPC title

• B05D2401/90

  at least one component of the composition being in supercritical state or close to supercritical state · CPC title